Genotype and risk of major bleeding during warfarin treatment.
Pharmacogenomics. 2014.
PMID: 25521356
Free PMC article.
Search Page
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 0 |
Search Results
45
results
Results by year
Citations
1 article found by citation matchingSearch results
Filters applied: . Clear all
Page 1
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
JAMA. 2017 Sep 26;318(12):1115-1124. doi: 10.1001/jama.2017.11469.
JAMA. 2017.
PMID: 28973620
Free PMC article.
Clinical Trial.
Whether genotype-guided warfarin dosing can prevent these adverse events is unknown. ...CONCLUSIONS AND RELEVANCE: Among patients undergoing elective hip or knee arthroplasty and treated with perioperative warfarin, genotype-guided warfarin dosi …
Whether genotype-guided warfarin dosing can prevent these adverse events is unknown. ...CONCLUSIONS AND RELEVANCE: Among patie …
Genotype and risk of major bleeding during warfarin treatment.
Pharmacogenomics. 2014 Dec;15(16):1973-83. doi: 10.2217/pgs.14.153.
Pharmacogenomics. 2014.
PMID: 25521356
Free PMC article.
AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. ...CONCLUSION: The CYP2C9*3 allele may double the risk of major …
AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of …
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
JAMA. 2019 Sep 3;322(9):834-842. doi: 10.1001/jama.2019.12085.
JAMA. 2019.
PMID: 31479138
Free PMC article.
Clinical Trial.
INTERVENTIONS: In a 2 2 factorial design, participants were randomized to a target INR of 1.8 (n = 823) or 2.5 (n = 827) and to either genotype-guided or clinically guided warfarin dosing. For the first 11 days of therapy, open-label warfarin dosing wa …
INTERVENTIONS: In a 2 2 factorial design, participants were randomized to a target INR of 1.8 (n = 823) or 2.5 (n = 827) and to either ge …
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Sci Rep. 2020 Jan 20;10(1):662. doi: 10.1038/s41598-019-57370-2.
Sci Rep. 2020.
PMID: 31959803
Free PMC article.
Warfarin care bundles (e.g. genotype-guided warfarin dosing, patient's self-testing [PST] or patient's self-management [PSM] and left atrial appendage closure) are based on the concept of combining several interventions to improve anticoagulatio …
Warfarin care bundles (e.g. genotype-guided warfarin dosing, patient's self-testing [PST] or patient's se …
The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12.
Cardiology. 2013.
PMID: 23774101
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is hindered by the risk of bleeding. The main reason for this risk is a narrow therapeutic index and a wide response variab …
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is h …
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.
Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):619-27. doi: 10.1002/pds.3769. Epub 2015 Apr 8.
Pharmacoepidemiol Drug Saf. 2015.
PMID: 25858232
Free PMC article.
We conducted a case-control study to assess the association between screening positive for moderate/severe alcohol misuse and the risk of major bleeding in a community sample of patients using warfarin. ...Stratified analyses demonstrated increased alc …
We conducted a case-control study to assess the association between screening positive for moderate/severe alcohol misuse and the risk …
Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials.
J Clin Pharm Ther. 2019 Apr;44(2):197-208. doi: 10.1111/jcpt.12782. Epub 2018 Dec 28.
J Clin Pharm Ther. 2019.
PMID: 30593674
Review.
WHAT IS KNOWN AND OBJECTIVE: Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of warfarin. ...Risk of bias of eligible RCTs was assessed with the Cochrane Collaboration's tool. ...
WHAT IS KNOWN AND OBJECTIVE: Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of …
Genotype-guided warfarin therapy: Still of only questionable value two decades on.
J Clin Pharm Ther. 2020 Jun;45(3):547-560. doi: 10.1111/jcpt.13127. Epub 2020 Mar 13.
J Clin Pharm Ther. 2020.
PMID: 32168383
METHODS: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical analysis of these was undertaken to identify factors that may account for poor clinical implementation of pre-treatment genotyping …
METHODS: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical an …
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Lancet. 1999 Feb 27;353(9154):717-9. doi: 10.1016/S0140-6736(98)04474-2.
Lancet. 1999.
PMID: 10073515
Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26-15.82]) and have increased risk of major bleeding complications (rate ratio 3.68 [1.43-9.50]) when compared with random …
Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26- …
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
Int J Cardiol. 2013 Oct 9;168(4):4234-43. doi: 10.1016/j.ijcard.2013.07.151. Epub 2013 Aug 7.
Int J Cardiol. 2013.
PMID: 23932037
Review.
BACKGROUND: The main challenge for warfarin anticoagulation is the risk for hemorrhagic complications. ...CYP2C9*3 is the main genetic risk factor for warfarin hemorrhagic complications....
BACKGROUND: The main challenge for warfarin anticoagulation is the risk for hemorrhagic complications. ...CYP2C9*3 is the main …